Drugmakers talked about precision oncology acquisitions, and a genetic testing firm discussed the use of artificial intelligence in predicting treatment response.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
The newly formed company will focus on building out a precision cancer therapy-based portfolio from existing and new product candidates.
NEC said the deal will bolster its cancer immunotherapy development programs, which are focused on ovarian cancer and head and neck cancer.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
Among Kiromic's platforms is an artificial intelligence product that combines genomic sequencing, proteomic, and clinical data to provide predictive algorithms.
The company has formalized an existing relationship by acquiring Pharmatech, hoping to directly integrate the firm's "right on time" trial matching service with its own molecular testing.
The firms will integrate Caris' molecular profiling services with Pharmatech's clinical trials recruitment and network services to further precision medicine.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
Last week's buys of two oncology labs will allow Quest to provide new cancer diagnostic technologies to communities lacking major cancer research centers, it said.